T1期局限性肾癌剜除平面浸润情况的病理学分析

李实, 于广海, 陶晓峰, 等. T1期局限性肾癌剜除平面浸润情况的病理学分析[J]. 临床泌尿外科杂志, 2022, 37(6): 457-460. doi: 10.13201/j.issn.1001-1420.2022.06.011
引用本文: 李实, 于广海, 陶晓峰, 等. T1期局限性肾癌剜除平面浸润情况的病理学分析[J]. 临床泌尿外科杂志, 2022, 37(6): 457-460. doi: 10.13201/j.issn.1001-1420.2022.06.011
LI Shi, YU Guanghai, TAO Xiaofeng, et al. Pathological analysis of the infiltration of the enucleation plane in stage T1 localized renal cell carcinoma[J]. J Clin Urol, 2022, 37(6): 457-460. doi: 10.13201/j.issn.1001-1420.2022.06.011
Citation: LI Shi, YU Guanghai, TAO Xiaofeng, et al. Pathological analysis of the infiltration of the enucleation plane in stage T1 localized renal cell carcinoma[J]. J Clin Urol, 2022, 37(6): 457-460. doi: 10.13201/j.issn.1001-1420.2022.06.011

T1期局限性肾癌剜除平面浸润情况的病理学分析

详细信息

Pathological analysis of the infiltration of the enucleation plane in stage T1 localized renal cell carcinoma

More Information
  • 目的 评估局限性肾癌在肾肿瘤剜除平面的浸润情况,探讨肾肿瘤剜除术良好肿瘤学预后的理论依据。方法 通过对T1期局限性肾癌分别实施后腹腔下根治性肾切除术(RLRN)、后腹腔镜下肾部分切除术(RLPN)及后腹腔镜下肾肿瘤剜除术(RLTE),在标本离体后进行肿瘤二次剜除以获得剜除标本及瘤床标本,对肾癌假包膜组织构成、特点及肿瘤浸润情况进行病理分析及统计学分析。结果 假包膜出现率为97.01%(65/67);假包膜平均厚度0.53 mm;假包膜受侵率为86.15%(56/65);假包膜受侵与肿瘤组织学类型不相关;与T分期及肾透明细胞癌ISUP细胞核分级相关。57例RLRN及RLPN离体标本进行剜除后的瘤床未发现肿瘤侵犯及肿瘤卫星灶。结论 局限性肾癌假包膜受侵概率也较高,但均未超过假包膜,肿瘤假包膜限制了肿瘤对包膜外肾组织的侵犯,并且通过对瘤床病理检测也未发现肿瘤浸润。对T1期局限性肾癌行肾肿瘤剜除术理论上安全、可靠。
  • 加载中
  • 图 1  标本处理

    图 2  肿瘤对假包膜及瘤床的浸润情况(×200)

    表 1  假包膜受侵情况与肿瘤特点 

    项目 假包膜未受侵 假包膜受侵 Z/χ2 P
    T分期 -1.980 0.048
      T1a 8 30
      T1b 1 26
    ISUP分级 -2.217 0.027
      1级 2 2
      2级 6 40
      3级 0 11
    组织学类型 2.540 0.468
      透明细胞癌 8 53
      嫌色细胞癌 0 1
      乳头状细胞癌 1 1
      甲状腺滤泡样癌 0 1
    下载: 导出CSV
  • [1]

    Minervini A, Campi R, Di Maida F, et al. Tumor-parenchyma interface and long-term oncologic outcomes after robotic tumor enucleation for sporadic renal cell carcinoma[J]. Urol Oncol, 2018, 36(12): 527. e1-527. e11. doi: 10.1016/j.urolonc.2018.08.014

    [2]

    Minervini A, di Cristofano C, Lapini A, et al. Histopathologic analysis of peritumoral pseudocapsule and surgical margin status after tumor enucleation for renal cell carcinoma[J]. Eur Urol, 2009, 55(6): 1410-1418. doi: 10.1016/j.eururo.2008.07.038

    [3]

    Roquero L, Kryvenko ON, Gupta NS, et al. Characterization of Fibromuscular Pseudocapsule in Renal Cell Carcinoma[J]. Int J Surg Pathol, 2015, 23(5): 359-363. doi: 10.1177/1066896915579198

    [4]

    Wang L, Feng J, Alvarez H, et al. Critical histologic appraisal of the pseudocapsule of small renal tumors[J]. Virchows Arch, 2015, 467(3): 311-317. doi: 10.1007/s00428-015-1797-5

    [5]

    李实, 于广海. 后腹腔镜肾肿瘤单纯剜除术及切除剜除方式在T1期肾癌的应用(附97例报告)[J]. 临床泌尿外科杂志, 2018, 33(5): 372-376, 381. http://lcmw.cbpt.cnki.net/WKC/WebPublication/paperDigest.aspx?paperID=a6365187-eec1-44e7-8bc6-d0bd1661b194

    [6]

    De Riese W, Reale E. The capsule of the renal cell carcinoma(clear cell phenotype)contains modified smooth muscle cells[J]. J Submicrosc Cytol Pathol, 1991, 23(2): 237-244.

    [7]

    Azhar RA, de Castro Abreu AL, Broxham E, et al. Histological analysis of the kidney tumor-parenchyma interface[J]. J Urol, 2015, 193(2): 415-422. doi: 10.1016/j.juro.2014.08.010

    [8]

    Minervini A, Rosaria Raspollini M, Tuccio A, et al. Pathological characteristics and prognostic effect of peritumoral capsule penetration in renal cell carcinoma after tumor enucleation[J]. Urol Oncol, 2014, 32(1): 50. e15-22. doi: 10.1016/j.urolonc.2013.07.018

    [9]

    Xu C, Lin C, Xu Z, et al. Tumor Enucleation vs. Partial Nephrectomy for T1 Renal Cell Carcinoma: A Systematic Review and Meta-Analysis[J]. Front Oncol, 2019, 9: 473. doi: 10.3389/fonc.2019.00473

    [10]

    Singer EA, Vourganti S, Lin KY, et al. Outcomes of patients with surgically treated bilateral renal masses and a minimum of 10 years of followup[J]. J Urol, 2012, 188(6): 2084-2088. doi: 10.1016/j.juro.2012.08.038

    [11]

    Dong W, Chen X, Huang M, et al. Long-Term Oncologic Outcomes After Laparoscopic and Robotic Tumor Enucleation for Renal Cell Carcinoma[J]. Front Oncol, 2020, 10: 595457.

    [12]

    董文, 欧德华, 高明等. 肾肿瘤剜除与标准肾部分切除术对局限性肾癌术后正常肾实质保护的比较[J]. 临床泌尿外科杂志, 2019, 34(1): 9-13. http://lcmw.cbpt.cnki.net/WKC/WebPublication/paperDigest.aspx?paperID=810d0db5-aba8-464d-a1d1-3c6abdd5be93

    [13]

    黄翼然. 从肾脏解剖和肾癌病理特征谈保留肾单位手术[J]. 临床泌尿外科杂志, 2016, 31(3): 195-197. http://lcmw.cbpt.cnki.net/WKC/WebPublication/paperDigest.aspx?paperID=06cbc877-15f8-403d-87ad-8f1962f2b263

    [14]

    邓永明, 赵晓智, 叶长晓等, 腹腔镜肾肿瘤剜除术治疗T1aN0M0期肾癌, 微创泌尿外科杂志, 2015, 4(1): 11-15. doi: 10.3969/j.issn.2095-5146.2015.01.003

    [15]

    Volpe A, Bollito E, Bozzola C, et al. Classification of Histologic Patterns of Pseudocapsular Invasion in Organ-Confined Renal Cell Carcinoma[J]. Clin Genitourin Cancer, 2016, 14(1): 69-75. doi: 10.1016/j.clgc.2015.07.020

    [16]

    Snarskis C, Calaway AC, Wang L, et al. Standardized Reporting of Microscopic Renal Tumor Margins: Introduction of the Renal Tumor Capsule Invasion Scoring System[J]. J Urol, 2017, 197(1): 23-30. doi: 10.1016/j.juro.2016.07.086

    [17]

    Lu Q, Ji C, Zhao X, et al. Histopathologic analysis of tumor bed and peritumoral pseudocapsule after in vitro tumor enucleation on radical nephrectomy specimen for clinical T1b renal cell carcinoma[J]. Urol Oncol, 2017, 35(10): 603. e15-603. e20. doi: 10.1016/j.urolonc.2017.05.017

  • 加载中

(2)

(1)

计量
  • 文章访问数:  1072
  • PDF下载数:  630
  • 施引文献:  0
出版历程
收稿日期:  2022-02-27
刊出日期:  2022-06-06

目录